Cefixime and Haematemesis - a phase IV clinical study of FDA data

Summary:

Haematemesis is reported as a side effect among people who take Cefixime (cefixime), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Lescol Xl, and have Dyslipidaemia.

The phase IV clinical study analyzes which people have Haematemesis when taking Cefixime. It is created by eHealthMe based on reports of 3,217 people who have side effects when taking Cefixime from the FDA, and is updated regularly.

What is Cefixime?

Cefixime has active ingredients of cefixime. eHealthMe is studying from 3,237 Cefixime users. Check the latest studies of Cefixime.

What is Haematemesis?

Haematemesis (vomiting of blood) is found to be associated with 1,458 drugs and 2,238 conditions by eHealthMe. Check the latest studies of Haematemesis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 17, 2026

3,217 people reported to have side effects when taking Cefixime.
Among them, 13 people (0.4%) have Haematemesis.

Among these 13 people:

How long have people been on Cefixime when they have Haematemesis? *

What is the gender of people who have Haematemesis when taking Cefixime? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Haematemesis when taking Cefixime? *

What are other drugs people take besides Cefixime? *

Zopiclone: 4 people, 30.77%
Xyzal: 4 people, 30.77%
Lescol Xl: 4 people, 30.77%
Furosemide: 3 people, 23.08%
Mucomyst: 2 people, 15.38%
Ciprofloxacin: 2 people, 15.38%
Cordarone: 2 people, 15.38%
Diltiazem Hydrochloride: 2 people, 15.38%
Escitalopram Oxalate: 2 people, 15.38%
Invega: 2 people, 15.38%

What are other side effects people have besides Haematemesis? *

Pain: 6 people, 46.15%
Nausea And Vomiting: 6 people, 46.15%
Haemoglobin Decreased: 6 people, 46.15%
Oedema Peripheral (superficial swelling): 6 people, 46.15%
High Blood Pressure: 6 people, 46.15%
Consciousness - Decreased: 5 people, 38.46%
General Physical Health Deterioration (weak health status): 5 people, 38.46%
International Normalised Ratio Increased: 5 people, 38.46%
Thirst: 5 people, 38.46%
Faeces Discolored: 5 people, 38.46%

What are the existing conditions these people have? *

Dyslipidaemia (abnormal amount of lipids): 4 people, 30.77%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 2 people, 15.38%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 15.38%
Aortic Valve Disease: 2 people, 15.38%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 7.69%
Schizophrenia, Paranoid Type (delusions and auditory hallucinations but relatively normal intellectual functioning and expression of affect): 1 person, 7.69%
High Blood Cholesterol: 1 person, 7.69%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Cefixime and have Haematemesis?

- Check whether Haematemesis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cefixime:

Cefixime (3,237 reports)

Haematemesis treatments and more:

Haematemesis (33,968 reports)

Browse all side effects of Cefixime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematemesis:

Haematemesis (1,458 drugs)

Browse all the conditions that are associated with Haematemesis:

Haematemesis (2,238 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cefixime (the active ingredients of Cefixime) and Cefixime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.